133 related articles for article (PubMed ID: 7752142)
21. Mechanism of cartilage destruction in osteoarthritis.
Ishiguro N; Kojima T; Poole AR
Nagoya J Med Sci; 2002 Nov; 65(3-4):73-84. PubMed ID: 12580533
[TBL] [Abstract][Full Text] [Related]
22. Coordinated regulation of hyaluronan and aggrecan content in the articular cartilage of immobilized and exercised dogs.
Haapala J; Lammi MJ; Inkinen R; Parkkinen JJ; Agren UM; Arokoski J; Kiviranta I; Helminen HJ; Tammi MI
J Rheumatol; 1996 Sep; 23(9):1586-93. PubMed ID: 8877929
[TBL] [Abstract][Full Text] [Related]
23. [Absolute risk for fracture and WHO guideline. Biological markers for osteoarthritis (OA)].
Date H; Yamada H; Kanaji A; Tajima K; Hayakawa K; Maehara K; Miyazaki K; Masuda H;
Clin Calcium; 2007 Jul; 17(7):1071-9. PubMed ID: 17607075
[TBL] [Abstract][Full Text] [Related]
24. High levels of aggrecan aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis.
Ratcliffe A; Grelsamer RP; Kiernan H; Saed-Nejad F; Visco D
Acta Orthop Scand Suppl; 1995 Oct; 266():111-5. PubMed ID: 8553838
[No Abstract] [Full Text] [Related]
25. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.
Kong SY; Stabler TV; Criscione LG; Elliott AL; Jordan JM; Kraus VB
Arthritis Rheum; 2006 Aug; 54(8):2496-504. PubMed ID: 16868970
[TBL] [Abstract][Full Text] [Related]
26. Examination of synovial fluid hyaluronan quantity and quality in stifle joints of dogs with osteoarthritis.
Venable RO; Stoker AM; Cook CR; Cockrell MK; Cook JL
Am J Vet Res; 2008 Dec; 69(12):1569-73. PubMed ID: 19046002
[TBL] [Abstract][Full Text] [Related]
27. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis.
Poole AR; Ionescu M; Swan A; Dieppe PA
J Clin Invest; 1994 Jul; 94(1):25-33. PubMed ID: 7518830
[TBL] [Abstract][Full Text] [Related]
28. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
[TBL] [Abstract][Full Text] [Related]
29. Alterations in cartilage type-II procollagen and aggrecan contents in synovial fluid in equine osteochondrosis.
Laverty S; Ionescu M; Marcoux M; Bouré L; Doizé B; Poole AR
J Orthop Res; 2000 May; 18(3):399-405. PubMed ID: 10937626
[TBL] [Abstract][Full Text] [Related]
30. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis.
Squires GR; Okouneff S; Ionescu M; Poole AR
Arthritis Rheum; 2003 May; 48(5):1261-70. PubMed ID: 12746899
[TBL] [Abstract][Full Text] [Related]
31. Serum concentrations of hyaluronan and proteoglycan in joint disease. Lack of association.
Hedin PJ; Weitoft T; Hedin H; Engström-Laurent A; Saxne T
J Rheumatol; 1991 Oct; 18(10):1601-5. PubMed ID: 1765988
[TBL] [Abstract][Full Text] [Related]
32. Joint biomarkers in idiopathic femoral head osteonecrosis: comparison with hip osteoarthritis.
Kato S; Yamada H; Terada N; Masuda K; Lenz ME; Morita M; Yoshihara Y; Henmi O
J Rheumatol; 2005 Aug; 32(8):1518-23. PubMed ID: 16078329
[TBL] [Abstract][Full Text] [Related]
33. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis.
Lohmander LS; Yoshihara Y; Roos H; Kobayashi T; Yamada H; Shinmei M
J Rheumatol; 1996 Oct; 23(10):1765-9. PubMed ID: 8895155
[TBL] [Abstract][Full Text] [Related]
34. [Biological markers of osteoarthritis].
Thonar EJ; Manicourt DH
Rev Rhum Ed Fr; 1994 Nov; 61(9 Pt 2):99S-102S. PubMed ID: 7858614
[TBL] [Abstract][Full Text] [Related]
35. Regional differences in the rise in blood levels of antigenic keratan sulfate and hyaluronan after chymopapain induced knee joint injury.
Rayan V; Thonar EJ; Chen LM; Lenz ME; Williams JM
J Rheumatol; 1998 Mar; 25(3):521-6. PubMed ID: 9517774
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis.
Lindhorst E; Vail TP; Guilak F; Wang H; Setton LA; Vilim V; Kraus VB
J Orthop Res; 2000 Mar; 18(2):269-80. PubMed ID: 10815829
[TBL] [Abstract][Full Text] [Related]
37. Immune responses to cartilage link protein and the G1 domain of proteoglycan aggrecan in patients with osteoarthritis.
Guerassimov A; Zhang Y; Cartman A; Rosenberg LC; Esdaile J; Fitzcharles MA; Poole AR
Arthritis Rheum; 1999 Mar; 42(3):527-33. PubMed ID: 10088776
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of interleukin-1 on hyaluronan and proteoglycan metabolism in two compartments of the matrix formed by articular chondrocytes maintained in alginate.
D'Souza AL; Masuda K; Otten LM; Nishida Y; Knudson W; Thonar EJ
Arch Biochem Biophys; 2000 Feb; 374(1):59-65. PubMed ID: 10640396
[TBL] [Abstract][Full Text] [Related]
39. Products resulting from cleavage of the interglobular domain of aggrecan in samples of synovial fluid collected from dogs with early- and late-stage osteoarthritis.
Innes JF; Little CB; Hughes CE; Caterson B
Am J Vet Res; 2005 Oct; 66(10):1679-85. PubMed ID: 16273897
[TBL] [Abstract][Full Text] [Related]
40. Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring.
Sandy JD; Plaas AH; Koob TJ
Acta Orthop Scand Suppl; 1995 Oct; 266():26-32. PubMed ID: 8553857
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
